Zenith Health

Why is Zenith Health Care Ltd falling/rising?

As of 03-Sep, Zenith Health Care Ltd's stock price is rising to 3.25, reflecting a 0.62% increase. This growth is driven by strong performance against the Sensex, positive momentum above key moving averages, and a significant rise in investor participation.

As of 03-Sep, Zenith Health Care Ltd's stock price is rising, currently at 3.25, with a change of 0.02 (0.62%) upwards. This increase can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 6.56% while the Sensex declined by 1.01%. Additionally, the stock has shown a positive trend with a consecutive gain over the last two days, resulting in a total return of 6.45% during this period.<BR><BR>Furthermore, Zenith Health Care is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward momentum. The rising investor participation is also noteworthy, with a delivery volume of 71.87k on September 2, which represents a significant increase of 296.62% compared to the 5-day average delivery volume. This suggests heightened interest and confidence among investors in the stock, contributing to its upward price movement.

Which are the latest news on Zenith Health?

Who are in the management team of Zenith Health?

The management team of Zenith Health includes Mahendra C Raycha (Chairman & Managing Director), Neela Raycha, Atul Thakkar (both Non Executive Directors), Gaurang Vora, Tejas Thakkar, Rajeshkumar M Thakkar (all Independent Directors), Akshit Raycha (Joint Managing Director), and Mihir Satishkumar Shah (Company Secretary & Compliance Officer). They are responsible for the company's strategic direction and regulatory compliance.

The management team of Zenith Health includes the following members:<BR><BR>1. **Mahendra C Raycha** - Chairman & Managing Director<BR>2. **Neela Raycha** - Non Executive Director<BR>3. **Atul Thakkar** - Non Executive Director<BR>4. **Gaurang Vora** - Independent Director<BR>5. **Tejas Thakkar** - Independent Director<BR>6. **Rajeshkumar M Thakkar** - Independent Director<BR>7. **Akshit Raycha** - Joint Managing Director<BR>8. **Mihir Satishkumar Shah** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

What does Zenith Health do?

Zenith Health Care Ltd manufactures pharmaceuticals, including tablets and injectables, and is a micro-cap company with a market cap of INR 17 Cr. As of June 2026, it reported net sales of 3 Cr and a net profit of 0 Cr.

Overview:<BR>Zenith Health Care Ltd is engaged in the manufacturing of pharmaceuticals, including tablets, capsules, ointments, and liquid injectables, and operates within the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History:<BR>Incorporated in 1994, Zenith Health Care Ltd is an ISO 9001:2008 & WHO-cGMP certified company. The latest quarterly results reported net sales and net profit for the period ending June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 17 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 105.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.05 <BR>Return on Equity: 2.16% <BR>Price to Book: 2.24<BR><BR>Contact Details:<BR>Address: 504 Iscon Elegance S G Road, Nr Ananddham Jain Derasar Ahmedabad Gujarat : 380051 <BR>Tel: 91-79-66168889/66168890 <BR>Email: mahendrazenith@hotmail.com <BR>Website: http://www.zenithhealthcare.com

Who are the peers of the Zenith Health?

Zenith Health's peers include Shree Ganesh Bio, Centuple Global, Colinz Labs, Bacil Pharma, Desh Rakshak, Dipna Pharmachem, Starsource Multi, Mono Pharmacare, and Saroja Pharma In. Centuple Global shows the highest 1-year return at 22.32%, while Zenith Health's return is -26.46%.

Peers: The peers of Zenith Health are Shree Ganesh Bio, Centuple Global, Colinz Labs, Bacil Pharma, Desh Rakshak, Dipna Pharmachem, Starsource Multi, Mono Pharmacare, and Saroja Pharma In.<BR><BR>Quality Snapshot: Excellent management risk is observed at Centuple Global, while Average management risk is found at Saroja Pharma In, and Below Average management risk is noted at Shree Ganesh Bio, Colinz Labs, Zenith Health, Desh Rakshak, Dipna Pharmachem, Mono Pharmacare, and the rest. Growth is Excellent at Dipna Pharmachem, Good at Centuple Global, and Below Average at Shree Ganesh Bio, Colinz Labs, Zenith Health, Desh Rakshak, Mono Pharmacare, and the rest. Capital Structure is Good at Centuple Global, Colinz Labs, and Zenith Health, while Below Average is found at Desh Rakshak, Dipna Pharmachem, Mono Pharmacare, Saroja Pharma In, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Centuple Global at 22.32%, while the peer with the lowest is Dipna Pharmachem at -73.42%. Zenith Health's own 1-year return is -26.46%, which is better than Dipna Pharmachem but worse than Centuple Global. Additionally, the six-month returns are negative for Centuple Global, Desh Rakshak, Dipna Pharmachem, and Bacil Pharma.

How big is Zenith Health?

As of 31st August, Zenith Health Care Ltd has a market capitalization of 17.00 Cr, with recent Net Sales of 10.80 Cr and a Net Profit of 0.16 Cr. The company has Shareholder's Funds of 7.42 Cr and Total Assets of 10.99 Cr as of March 2026.

As of 31st August, Zenith Health Care Ltd has a market capitalization of 17.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Zenith Health reported Net Sales of 10.80 Cr and a Net Profit of 0.16 Cr.<BR><BR>As of March 2026, the company has Shareholder's Funds amounting to 7.42 Cr and Total Assets of 10.99 Cr.

Should I buy, sell or hold Zenith Health Care Ltd?

Are Zenith Health Care Ltd latest results good or bad?

Zenith Health Care Ltd's latest results are concerning, showing a net loss of ₹0.34 crore for Q4 FY26 compared to a profit last year, with revenue down 23.62% year-on-year and a negative operating margin. Overall, the financial metrics indicate significant operational challenges, leading to a "STRONG SELL" recommendation for investors.

Zenith Health Care Ltd's latest results are concerning and indicate a significant decline in performance. For Q4 FY26, the company reported a net loss of ₹0.34 crore, a stark contrast to a profit of ₹0.11 crore in the same quarter last year. This reflects a deterioration in profitability.<BR><BR>Revenue also fell by 23.62% year-on-year to ₹2.62 crore, although there was a slight quarter-on-quarter improvement of 5.65%. The operating margin collapsed to -17.56%, down from a marginally positive 0.87% a year earlier, highlighting severe operational challenges and cost management issues.<BR><BR>The company's return on equity (ROE) stands at 5.98%, which is below industry standards, indicating poor capital efficiency. Additionally, the stock has underperformed significantly over the past year, declining 29.35% compared to the Sensex's 8.40% fall.<BR><BR>Overall, the financial metrics suggest that Zenith Health Care is facing critical operational challenges, and the outlook appears bleak, with multiple red flags indicating a "STRONG SELL" recommendation for investors.

When is the next results date for Zenith Health Care Ltd?

The next results date for Zenith Health Care Ltd is 29 May 2026.

The next results date for Zenith Health Care Ltd is scheduled for 29 May 2026.

How has been the historical performance of Zenith Health?

Zenith Health's historical performance shows a decline in net sales from INR 22.36 crore in March 2022 to INR 11.33 crore in March 2025, with fluctuating profits and stable total assets and liabilities. Overall, the company has faced significant financial fluctuations, particularly in sales and profits.

Answer:<BR>The historical performance of Zenith Health shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Zenith Health's net sales have seen a decline from INR 22.36 crore in March 2022 to INR 11.33 crore in March 2025, with a notable drop in March 2024 to INR 14.47 crore and INR 13.13 crore in March 2023. The total operating income followed a similar pattern, decreasing from INR 22.36 crore in March 2022 to INR 11.33 crore in March 2025. The company's total expenditure, excluding depreciation, also decreased from INR 21.90 crore in March 2022 to INR 11.24 crore in March 2025. Operating profit (PBDIT) has fluctuated, peaking at INR 0.98 crore in March 2022 and dropping to INR 0.52 crore by March 2025. Profit before tax remained stable at INR 0.28 crore in both March 2024 and March 2025, while profit after tax decreased from INR 0.31 crore in March 2022 to INR 0.07 crore in March 2025. The company's total assets increased from INR 8.23 crore in March 2020 to INR 10.88 crore in March 2025, while total liabilities rose from INR 8.44 crore in March 2021 to INR 10.88 crore in March 2025. Cash flow from operating activities remained at zero in March 2025, with a cash outflow from investing activities of INR -1.00 crore. Overall, Zenith Health has experienced significant fluctuations in its financial performance, particularly in sales and profits, over the past several years.

Who are the top shareholders of the Zenith Health?

The top shareholders of Zenith Health include Mahendra Chatrabhuj Raycha with 12.29%, and Sharpline Trading Co. Pvt. Ltd. with 3.29%. Individual investors hold a significant 64.12%, while there are no institutional or foreign institutional investors.

The top shareholders of Zenith Health include Mahendra Chatrabhuj Raycha, who holds the highest promoter stake at 12.29%. The highest public shareholder is Sharpline Trading Co. Pvt. Ltd., with a holding of 3.29%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 64.12% of the shares. There are no institutional investors or foreign institutional investors currently holding shares in the company.

Is Zenith Health overvalued or undervalued?

As of July 22, 2024, Zenith Health is considered overvalued with a PE ratio of 24.18 and an EV to EBITDA of 21.55, especially when compared to peers like Sun Pharma and Cipla, and its stock has underperformed against the Sensex.

As of 22 July 2024, Zenith Health's valuation grade has moved from very expensive to risky, indicating a significant shift in its market perception. The company appears to be overvalued given its current metrics, with a PE ratio of 24.18, an EV to EBITDA of 21.55, and a PEG ratio of 0.00. These ratios suggest that while the company is generating some earnings, it is not doing so efficiently relative to its price.<BR><BR>In comparison to its peers, Zenith Health's valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla, which is rated as attractive, has a PE ratio of 22.99 and an EV to EBITDA of 15.93. This peer comparison reinforces the notion that Zenith Health is overvalued in the current market context. Additionally, the company's stock has underperformed against the Sensex, particularly in the year-to-date and three-year periods, which further supports the case for its overvaluation.

What is the technical trend for Zenith Health?

As of May 20, 2025, Zenith Health's technical trend has shifted to bearish, supported by negative signals from the MACD, RSI, and moving averages, despite a mildly bullish KST.

As of 20 May 2025, the technical trend for Zenith Health has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly and monthly MACD, both showing bearish signals. The RSI on the monthly timeframe is also bearish, reinforcing the negative outlook. Daily moving averages confirm a bearish trend. While the KST on the weekly is mildly bullish, it does not outweigh the overall bearish sentiment from the other indicators. Bollinger Bands are mildly bearish on both weekly and monthly timeframes. Overall, the technical indicators suggest a bearish trend with significant weakness.

Has Zenith Health declared dividend?

No Dividend History Available